Mismatch between cancer genetics counseling and testing guidelines and physician practices

July 25, 2011, Wiley

A new analysis has found that many doctors report that they do not appropriately offer breast and ovarian cancer counseling and testing services to their female patients. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that efforts are needed to encourage these services for high-risk women and discourage them for average-risk women.

Women with mutations in the BRCA1 or have a substantially increased risk of developing breast and ovarian cancer, but there are medical treatments that can dramatically decrease their risk. Therefore, genetic counseling and testing are recommended for women at high risk of developing breast or ovarian cancer because of a personal or family history indicative of a BRCA 1/2 mutation; however, they are not recommended for those at average risk because the harms of treatment outweigh the benefits.

Little is known about whether physicians are adhering to recommendations related to genetic counseling and testing for women at average and high risk of ovarian cancer. To investigate, Katrina Trivers, PhD, MSPH, of the in Atlanta, and her colleagues surveyed 3,200 U.S. , general internists, and obstetrician-gynecologists with a questionnaire that asked about the services they would provide to women at annual exams, including how frequently they would refer women to genetic counseling or offer BRCA 1/2 testing. Scenarios in the questionnaire varied the patients' characteristics, such as age, race, , and ovarian .

A total of 1,878 physicians (62 percent) responded to the survey. For high-risk women, less than half (41 percent) of the physicians reported that they would recommend referral for genetic counseling or testing, consistent with guidelines. Twenty-nine percent of physicians reported that they would sometimes or always refer average-risk women for genetic counseling and testing. "Despite the existence of evidence-based guidelines on referral for and testing for hereditary breast and ovarian cancer, many physicians report practices contrary to these recommendations," said Dr. Trivers. She noted that when high-risk women do not receive these services, they could miss out on important interventions that can decrease their risk. On the other hand, when physicians refer average-risk women for counseling and testing, this is an inefficient use of resources that is associated with, at most, a small clinical benefit.

The investigators found that physicians reported that they were more likely to follow guideline recommendations when they were able to accurately estimate their patients' risks of ovarian cancer.

Related Stories

Recommended for you

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.